101. [Treatment of low-pressure vascular malformations by injection of Ethibloc. Study of 19 cases and analysis of complications].
- Author
-
Baud AV, Breton P, Guibaud L, and Freidel M
- Subjects
- Adult, Child, Child, Preschool, Diatrizoate adverse effects, Drug Combinations, Fatty Acids adverse effects, Female, Granuloma etiology, Head and Neck Neoplasms therapy, Hemangioma therapy, Humans, Infant, Infant, Newborn, Lung Neoplasms therapy, Male, Propylene Glycols adverse effects, Retrospective Studies, Sclerosing Solutions adverse effects, Sclerotherapy adverse effects, Treatment Outcome, Zein adverse effects, Arteriovenous Malformations therapy, Diatrizoate therapeutic use, Fatty Acids therapeutic use, Lymphangioma, Cystic therapy, Propylene Glycols therapeutic use, Sclerosing Solutions therapeutic use, Sclerotherapy methods, Zein therapeutic use
- Abstract
We retrospectively studied the cases of 19 patients suffering from low flow vascular malformations who were treated with Ethibloc sclerotherapy. Out of 10 venous angiomas, 5 entirely disappeared, 3 considerably decreased and 2 remained unaltered. Out of 7 cystic lymphangiomas, 7 were completely cured and in the 2 other cases, outcome was quite good. Post-treatment complications consisted in a local inflammatory reaction. This reaction occurred immediately and disappeared within a few days without after-effects. It materialized as an Ethibloc exteriorization among 5 patients suffering from venous angiomas and 3 patients suffering from lymphangiomas and as an inflammatory lump for 2 venous angiomas carriers and for 4 lymphangiomas carriers. This lump was located at the puncture point of the product and it was due to some Ethibloc residue. Fourteen of these local reactions spontaneously decreased; 5 of them required a surgical operation but in all cases, after-effects were minor. These satisfactory results (volume decreasing in 90% of the malformations) as well as the mildness of the side effects encourage to use Ethibloc in the treatment of low flow vascular malformations. In our experience, Ethibloc is particularly appropriate for the treatment of large lymphangiomas.
- Published
- 2000